Alofanib (RPT835) is primarily investigated for its potential in cancer therapy, specifically as a selective inhibitor of focal adhesion kinase (FAK), a protein involved in tumor growth, survival, and metastasis. By inhibiting FAK, Alofanib disrupts signaling pathways that promote cancer cell proliferation and resistance to apoptosis, making it a candidate for use in solid tumors. It has shown promise in preclinical models for enhancing the efficacy of other anticancer agents, particularly in tumors with high FAK expression such as ovarian, lung, and pancreatic cancers. Its application is also being explored in combination with immune checkpoint inhibitors, where FAK inhibition may help overcome immunosuppression in the tumor microenvironment, thereby improving response to immunotherapy.